Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma

European Urology

Volumn 42, Issue 2, 2002, Pages 167-174

  Kaasinen, Eero ^a   Rintala, Erkki ^b   Hellström, Pekka ^c   Viitanen, Jouko ^d   Juusela, Harri ^e   Rajala, Pertti ^f   Korhonen, Heikki ^g   Liukkonen, Tapani ^h  

^a HYVINKÄÄ HOSPITAL   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d NORTH KARELIA CENTRAL HOSPITAL   (Finland)

^e JORVI HOSPITAL   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g SATAKUNTA CENTRAL HOSPITAL   (Finland)

^h MIKKELI CENTRAL HOSPITAL   (Finland)

Author keywords

BCG; Mitomycin C; Perioperative instillation; Prognostic factors; Recurrent superficial bladder carcinoma; Single instillation; Timing of instillation

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; MITOMYCIN C; RECOMBINANT ALPHA2B INTERFERON; ANTINEOPLASTIC ANTIBIOTIC; IMMUNOLOGICAL ADJUVANT; MITOMYCIN;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SUPERFICIAL CANCER; TREATMENT OUTCOME; TUMOR VOLUME; BLADDER TUMOR; DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; BLADDER NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; MALE; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 0036668380     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00260-9     Document Type: Article

References (24)

1. The management of superficial bladder cancer
2. Factors affecting recurrence and progression in superficial bladder tumours
3. Clinical characterization of risk profiles
4. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: Report from the British Medical Research Council subgroup on superficial bladder cancer (Urological Cancer Working Party)
5. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: A European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial
6. A prospective European Organization for Research Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder
7. Transurethral resection with perioperative instillation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: A prospective randomized multicenter study - FinnBladder III
8. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: A prospective, randomized controlled study
9. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow up
10. Effectiveness of a single immediate mitomycin C instillation in patients with low-risk superficial bladder cancer: Short and long-term followup
11. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial
12. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment
13. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer
14. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer
15. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma
16. Survival analysis
17. Superficial bladder tumors (stage pTa, grades 1 and 2): The importance of recurrence pattern following initial resection
18. Stage progression in Ta papillary urothelial tumors: Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy
19. Does the surgeon have an impact in the outcome of patients with stage Ta-T1 TCC of the bladder? Results of an EORTC quality control study on TURBT
20. A controlled trial of single dose intravesical adriamycin in superficial bladder tumours
21. Urothelial susceptibility to tumor cell implantation: Influence of cauterization
22. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder
23. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: Results of a European Organization for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin